Cynata Therapeutics Limited is an Australian clinical-stage biotechnology company developing disruptive regenerative medicine products.We are the leading company worldwide in the development of iPSC-derived cell therapies.

By using our unique manufacturing platform, Cymerus™, which enables us to economically produce therapeutic mesenchymal stem cells (MSCs) at scale with a consistent quality, we are able to overcome the inherent challenges in first generation methods of manufacturing MSCs for therapeutic use.